Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.

Journal Article (Journal Article;Multicenter Study)

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a multicenter retrospective study including patients ≥16 years of age with stage I-II NLPHL diagnosed from 1995 through 2018 who underwent all forms of management, including radiotherapy (RT), combined modality therapy (CMT; RT+chemotherapy [CT]), CT, observation after excision, rituximab and RT, and single-agent rituximab. End points were progression-free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age of 39 years: 72.3% were men, and 54.9% had stage I disease. Median follow-up was 5.5 years (interquartile range, 3.1-10.1). Five-year PFS and OS in the entire cohort were 87.1% and 98.3%, respectively. Primary management was RT alone (n = 257; 46.0%), CMT (n = 184; 32.9%), CT alone (n = 47; 8.4%), observation (n = 37; 6.6%), rituximab and RT (n = 19; 3.4%), and rituximab alone (n = 15; 2.7%). The 5-year PFS rates were 91.1% after RT, 90.5% after CMT, 77.8% after CT, 73.5% after observation, 80.8% after rituximab and RT, and 38.5% after rituximab alone. In the RT cohort, but not the CMT cohort, variant immunoarchitectural pattern and number of sites >2 were associated with worse PFS (P < .05). Overall, 21 patients (3.8%) developed large-cell transformation, with a significantly higher transformation rate in those with variant immunoarchitectural pattern (P = .049) and number of involved sites >2 (P = .0006). OS for patients with stage I-II NLPHL was excellent after all treatments.

Full Text

Duke Authors

Cited Authors

  • Binkley, MS; Rauf, MS; Milgrom, SA; Pinnix, CC; Tsang, R; Dickinson, M; Ng, AK; Roberts, KB; Gao, S; Balogh, A; Ricardi, U; Levis, M; Casulo, C; Stolten, M; Specht, L; Plastaras, JP; Wright, C; Kelsey, CR; Brady, JL; Mikhaeel, NG; Hoppe, BS; Terezakis, SA; Picardi, M; Della Pepa, R; Kirova, Y; Akhtar, S; Maghfoor, I; Koenig, JL; Jackson, C; Song, E; Sehgal, S; Advani, RH; Natkunam, Y; Constine, LS; Eich, HT; Wirth, A; Hoppe, RT

Published Date

  • June 25, 2020

Published In

Volume / Issue

  • 135 / 26

Start / End Page

  • 2365 - 2374

PubMed ID

  • 32211877

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood.2019003877


  • eng

Conference Location

  • United States